Hypoxia, Latency and Reactivation in M.tuberculosis
Hypoxia, Latency and Reactivation in M.tuberculosis
批准号:
6450621
负责人:
DAVID R SHERMAN
金额:
$16.66万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-09-15 至 2007-02-28
中文摘要
描述(由申请人提供):致病成功的核心
结核分枝杆菌(MTB)是其在人体内持续存在的能力,
长期处于潜伏状态,不会引起任何明显的疾病症状。
大约三分之一的世界人口窝藏潜在的MTB,
使结核病控制工作复杂化。潜伏性肺结核患者
在一生中有10%的机会患上活动性疾病,
这样的人感染艾滋病毒,复发结核病的风险就会增加
每年增长8 - 10%。人类宿主体内的低血糖症广泛存在于
被认为对潜伏性结核病的发展至关重要,但MTB
对缺氧的适应性反应目前知之甚少。的目标
这个建议是定义结核分枝杆菌缺氧反应,因为它与潜伏期有关
和重新激活。我们将机械地剖析这种反应,并分析
低氧在潜伏性结核病和再激活中的作用。这项建议会
定义其对氧张力降低的反应包括MTB的基因
缺氧调节子我们还将关注MTB α-晶体蛋白(Acr),
微需氧菌强烈诱导的低氧反应
条件我们将确定表达的具体条件,
α-晶状体蛋白及其调节剂是实现潜伏期或
重新激活最后,我们将剖析α-晶体蛋白调节
确定氧气张力控制的精确机制的机器
MTB基因表达。其结果将是更好的工具来应对威胁,
超过10亿人患有潜伏性结核病,其中数百万人
现在或即将同时感染人类免疫缺陷病毒,艾滋病病毒。
英文摘要
DESCRIPTION (Provided by the applicant): Central to the pathogenic success of
Mycobacterium tuberculosis (MTB) is its ability to persist within humans for
long periods in a latent state, without causing any overt disease symptoms.
Roughly one-third of the world population harbors latent MTB, greatly
complicating efforts at tuberculosis control. A person with latent tuberculosis
has about a 10 percent lifetime chance of developing active disease, and when
such a person contracts HIV, the risk of developing reactivation TB increases
to 8 - 10 percent per year. Hypoxic conditions within the human host are widely
regarded as crucial for development of latent tuberculosis, but the MTB
adaptive response to hypoxia is at present very poorly understood. The goal of
this proposal is to define the MTB hypoxic response as it relates to latency
and reactivation. We will mechanistically dissect this response and analyze the
role of hypoxia in latent tuberculosis and reactivation. This proposal will
define the genes whose response to reduced oxygen tension comprises the MTB
hypoxia regulon. We will also focus on MTB alpha-crystallin (Acr), a component
of the hypoxic response that is powerfully induced by microaerophilic
conditions. We will determine the specific conditions in which expression of
alpha-crystallin and its regulators is necessary for achieving latency or
reactivation. Finally, we will dissect the alpha-crystallin regulatory
machinery to determine the precise mechanisms by which oxygen tension controls
MTB gene expression. The result will be better tools to confront the threat to
more than one billion persons with latent tuberculosis, millions of whom are
now or will soon be co-infected the the human immunodeficiency virus, HIV.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Drug tolerance, bacterial heterogeneity and adverse TB treatment outcomes
-
批准号:10665037
-
项目类别:
-
资助金额:$13.32万
-
财政年份:2021
-
负责人:DAVID R SHERMAN
-
依托单位:
A multifactorial pipeline to dissect combinatorial drug efficacy in Tuberculosis
-
批准号:10117593
-
项目类别:
-
资助金额:$73.08万
-
财政年份:2021
-
负责人:DAVID R SHERMAN
-
依托单位:
Drug tolerance, bacterial heterogeneity and adverse TB treatment outcomes
-
批准号:10493290
-
项目类别:
-
资助金额:$14.37万
-
财政年份:2021
-
负责人:DAVID R SHERMAN
-
依托单位:
A multifactorial pipeline to dissect combinatorial drug efficacy in Tuberculosis
-
批准号:10669196
-
项目类别:
-
资助金额:$72.12万
-
财政年份:2021
-
负责人:DAVID R SHERMAN
-
依托单位:
A multifactorial pipeline to dissect combinatorial drug efficacy in Tuberculosis
-
批准号:10465068
-
项目类别:
-
资助金额:$70.51万
-
财政年份:2021
-
负责人:DAVID R SHERMAN
-
依托单位:
Drug tolerance, bacterial heterogeneity and adverse TB treatment outcomes
-
批准号:10271651
-
项目类别:
-
资助金额:$56.87万
-
财政年份:2021
-
负责人:DAVID R SHERMAN
-
依托单位:
Drug tolerance, bacterial heterogeneity and adverse TB treatment outcomes
-
批准号:10907961
-
项目类别:
-
资助金额:$33.99万
-
财政年份:2021
-
负责人:DAVID R SHERMAN
-
依托单位:
Project 2: Response to Treatment
-
批准号:10339374
-
项目类别:
-
资助金额:$74.61万
-
财政年份:2018
-
负责人:DAVID R SHERMAN
-
依托单位:
Parallel Microscopic Determination of Fitness (PMDF) to Assess Growth and Viability of Mycobacterium tuberculosis
-
批准号:9089849
-
项目类别:
-
资助金额:$23.63万
-
财政年份:2015
-
负责人:DAVID R SHERMAN
-
依托单位:
Bacterial Determinants of TB Progression
-
批准号:8577274
-
项目类别:
-
资助金额:$58.47万
-
财政年份:2013
-
负责人:DAVID R SHERMAN
-
依托单位:
Data Management and Resource Dissemination Core
-
批准号:8577291
-
项目类别:
-
资助金额:$17.88万
-
财政年份:2013
-
负责人:DAVID R SHERMAN
-
依托单位:
2013 Tuberculosis Drug Development GRC
-
批准号:8520841
-
项目类别:
-
资助金额:$0.8万
-
财政年份:2013
-
负责人:DAVID R SHERMAN
-
依托单位:
2011 Gordon Research Conference on Tuberculosis Drug Development
-
批准号:8125495
-
项目类别:
-
资助金额:$0.8万
-
财政年份:2011
-
负责人:DAVID R SHERMAN
-
依托单位:
A Novel Clock to Monitor M. tuberculosis in vivo
-
批准号:7844978
-
项目类别:
-
资助金额:$24.1万
-
财政年份:2009
-
负责人:DAVID R SHERMAN
-
依托单位:
A Novel Clock to Monitor M. tuberculosis in vivo
-
批准号:7574365
-
项目类别:
-
资助金额:$26.47万
-
财政年份:2009
-
负责人:DAVID R SHERMAN
-
依托单位:
Hypoxia, Latency and Reactivation in M.tuberculosis
-
批准号:7016314
-
项目类别:
-
资助金额:$32.87万
-
财政年份:2002
-
负责人:DAVID R SHERMAN
-
依托单位:
Hypoxia, Latency and Reactivation in M.tuberculosis
-
批准号:6655602
-
项目类别:
-
资助金额:$34.88万
-
财政年份:2002
-
负责人:DAVID R SHERMAN
-
依托单位:
Hypoxia, Latency and Reactivation in M.tuberculosis
-
批准号:6857094
-
项目类别:
-
资助金额:$33.68万
-
财政年份:2002
-
负责人:DAVID R SHERMAN
-
依托单位:
Hypoxia, Latency and Reactivation in M.tuberculosis
-
批准号:6725521
-
项目类别:
-
资助金额:$35.1万
-
财政年份:2002
-
负责人:DAVID R SHERMAN
-
依托单位:
Hypoxia, Latency and Reactivation in M tuberculosis
-
批准号:6346504
-
项目类别:
-
资助金额:$32.15万
-
财政年份:2001
-
负责人:DAVID R SHERMAN
-
依托单位: